PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The F...(ports licensing aircraft leasing fixed b...)

About PROLOR Biotech

PROLOR Biotech, Inc. is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins, and PROLOR is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. The company's long-acting human growth hormone drug candidate, which is expected to enter clinical trials in the coming months, has the potential to allow an administration regimen of a single weekly injection or even a single injection every two weeks, compared with the daily injection regimen most patients have to comply with today. For more information on PROLOR, visit www.prolor-biotech.com.

Safe Harbor Statement: This press release contains forward-looking statements, including statements regarding the results of current studies and preclinical experiments and the effectiveness of PROLOR's long-acting protein programs, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect PROLOR's business and prospects, including the risks that PROLOR may not succeed in developing any commercial products based upon its long-acting protein technology, including any long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve the expected
'/>"/>